A Phase 2 interventional study of Empasiprubart IV and Placebo IV in AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) and MG - Myasthenia Gravis, sponsored by argenx. Recruiting at 19 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Greece, Spain, Belgium, Japan, Netherlands, Italy
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Myasthenia Gravis by argenx — 9 open to participants now, 12 under way, 5 of them phase 3. Myasthenia Gravis · argenx.
Among the 18 studies in Myasthenia Gravis by argenx, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 18th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →9 of the 18 studies in Myasthenia Gravis by argenx are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in Italy
Ages 18+
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
argenx · Sites in United States
Ages 18+
argenx · Sites in United States, Austria, Belgium and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 10 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 40 is close to the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 70 across the 14 interventional studies, 190 across the 4 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
4 of the studies in Myasthenia Gravis by argenx that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT07673627argenxADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis | 2027-10 |
| NCT07595653argenxA Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Myasthenia Gravis by argenx, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
The aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG).
The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170
More information can be found here: https://clinicaltrials.argenx.com/adaptforward2
Once the master protocol and ISA2 screening periods are completed, eligible participants will be randomized to receive empasiprubart IV or placebo in the double-blinded treatment period (DBTP). All participants will then receive open-label efgartigimod PH20 SC PFS in the safety follow-up period.
The study duration for each participant is approximately up to 45 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive empasiprubart IV in the DBTP
Biological: Empasiprubart IV
Participants receive placebo IV in the DBTP
Other: Placebo IV
Participants receive open-label efgartigimod PH20 SC PFS in the safety follow-up period
Combination Product: Efgartigimod PH20 SC PFS
Intravenous infusions of empasiprubart
Intravenous infusions of placebo
Subcutaneous administration of efgartigimod PH20 via pre-filled syringe (PFS)
Incidence of adverse events and serious adverse events in the DBTP
Time frame: Up to 12 weeks
MG-ADL total score change from baseline at week 12
The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (normal symptoms) to 24 (most severe symptoms)
Time frame: Up to 12 weeks
QMG total score change from baseline at week 12
The Quantitative myasthenia gravis (QMG) includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no disease severity) to 39 (highest disease severity)
Time frame: Up to 12 weeks
MG-ADL total score change from baseline over time up to week 12
The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (normal symptoms) to 24 (most severe symptoms)
Time frame: Up to 12 weeks
QMG total score change from baseline over time up to week 12
The Quantitative myasthenia gravis (QMG) includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no disease severity) to 39 (highest disease severity)
Time frame: Up to 12 weeks
Proportion of participants reaching MSE at any point by week 12
MSE: Minimal symptom expression
Time frame: Up to 12 weeks
Proportion of participants who have ≥3-point reduction in MG-ADL at week 12
The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (normal symptoms) to 24 (most severe symptoms).
Time frame: Up to 12 weeks
Proportion of participants who have ≥5-point reduction in QMG at week 12
The Quantitative myasthenia gravis (QMG) includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no disease severity) to 39 (highest disease severity).
Time frame: Up to 12 weeks
Proportion of participants who have a positive PASS at week 12
PASS: Patient acceptable symptom state
Time frame: Up to 12 weeks
Proportion of participants who have a 50% MG-ADL total score improvement at week 12
The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (normal symptoms) to 24 (most severe symptoms).
Time frame: Up to 12 weeks
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Greece, Spain, Belgium, Japan, Netherlands, Italy
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empasiprubart